Strikingly, in vivo administration of β-CLA, while reducing the level of Ala to a similar extent as in vitro (Figure 8E), largely reduced the tumor burden (Figure 8, F and G) that was accompanied by reduced mTORC1 and cell proliferation indicated by p-S6, p-4EBP1, and PCNA (Figure 8, H and I). This evidence concerns the gene RPS6 and neoplasm.